NASDAQ:EXAS Exact Sciences - EXAS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. $67.86 +1.60 (+2.41%) (As of 03/31/2023 02:33 PM ET) Add Compare Share Share Today's Range$65.81▼$68.3850-Day Range$60.05▼$70.7752-Week Range$29.27▼$76.94Volume1.58 million shsAverage Volume2.51 million shsMarket Capitalization$12.09 billionP/E RatioN/ADividend YieldN/APrice Target$74.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Exact Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside9.2% Upside$74.14 Price TargetShort InterestHealthy6.95% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.76Based on 7 Articles This WeekInsider TradingSelling Shares$3.92 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.76) to ($2.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector206th out of 1,009 stocksMedical Laboratories Industry6th out of 24 stocks 2.3 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.14, Exact Sciences has a forecasted upside of 9.2% from its current price of $67.88.Amount of Analyst CoverageExact Sciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.95% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Exact Sciences has recently decreased by 5.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 77.37% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private colorectal cancer diagnostics services" product. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.55. Previous Next 2.6 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Exact Sciences this week, compared to 5 articles on an average week.Search InterestOnly 41 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,915,586.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions90.30% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($2.76) to ($2.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -19.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -19.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exact Sciences (NASDAQ:EXAS) StockEXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.Read More Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Stock News HeadlinesMarch 29, 2023 | finance.yahoo.comEmergent Biosolutions (EBS) Down 28.1% Since Last Earnings Report: Can It Rebound?March 23, 2023 | finance.yahoo.comCathie Wood Watch: While Others Sell Block, Ark Is BuyingMarch 31, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 22, 2023 | finance.yahoo.comCathie Wood Watch: Ark Gets Back into IntuitMarch 17, 2023 | finance.yahoo.comCathie Wood Watch: Ark Dumps Eight Figures Worth of TwilioMarch 16, 2023 | finance.yahoo.comExact Sciences (EXAS) Stock Moves -0.16%: What You Should KnowMarch 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Illumina (ILMN) and Tandem Diabetes Care (TNDM)March 14, 2023 | finance.yahoo.comCathie Wood Watch: Ark Buys Block, TeslaMarch 31, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 11, 2023 | benzinga.comExact Sciences Stock (NASDAQ:EXAS), Analyst Ratings, Price Targets, PredictionsMarch 8, 2023 | finance.yahoo.comCathie Wood Watch: Ark Buys Robinhood AgainMarch 8, 2023 | nasdaq.comARKK, ZM, ROKU, EXAS: Large Inflows Detected at ETFMarch 7, 2023 | finance.yahoo.comExact Sciences (EXAS) Stock Moves -1.42%: What You Should KnowMarch 7, 2023 | finance.yahoo.comCathie Wood Watch: Ark Buys RobinhoodMarch 6, 2023 | finance.yahoo.comCathie Wood Watch: Ark Again Trades Coinbase, DraftKingsMarch 5, 2023 | benzinga.comExact Sciences Stock (NASDAQ:EXAS), Guidance and ForecastMarch 2, 2023 | finance.yahoo.comColon-cancer rates are increasing among people in their 40s — and youngerMarch 2, 2023 | finance.yahoo.comCathie Wood Watch: Ark Pares Exact Sciences, Other HoldingsFebruary 24, 2023 | finance.yahoo.comCathie Wood Watch: Ark Again Pares DraftKings StakeFebruary 23, 2023 | finance.yahoo.comExact Sciences Corporation (NASDAQ:EXAS) Q4 2022 Earnings Call TranscriptFebruary 23, 2023 | finance.yahoo.comExact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior NotesFebruary 23, 2023 | finance.yahoo.comCathie Wood Watch: Ark Continues Coinbase Buying; Pares a Gambling StockFebruary 22, 2023 | bizjournals.comExact Sciences reports record revenue driven by Cologuard salesFebruary 22, 2023 | msn.comCanaccord Genuity Maintains Buy Rating for Exact Sciences: Here's What You Need To KnowFebruary 22, 2023 | finance.yahoo.comExact Sciences (EXAS) Q4 Earnings Top Estimates, Margin FallsFebruary 22, 2023 | finance.yahoo.comExact Sciences, A Top 5% Stock, Beat Quarterly ExpectationsFebruary 21, 2023 | msn.comExact Sciences GAAP EPS of -$0.72 beats by $0.11, revenue of $552.9M beats by $27.29MSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Company Calendar Last Earnings2/21/2023Today3/31/2023Next Earnings (Estimated)4/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,400Year Founded1995Price Target and Rating Average Stock Price Forecast$74.14 High Stock Price Forecast$92.00 Low Stock Price Forecast$55.00 Forecasted Upside/Downside+11.9%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-623,510,000.00 Net Margins-29.92% Pretax Margin-30.35% Return on Equity-19.76% Return on Assets-9.80% Debt Debt-to-Equity Ratio0.73 Current Ratio2.38 Quick Ratio2.09 Sales & Book Value Annual Sales$2.08 billion Price / Sales5.67 Cash FlowN/A Price / Cash FlowN/A Book Value$17.13 per share Price / Book3.87Miscellaneous Outstanding Shares178,220,000Free Float175,900,000Market Cap$11.81 billion OptionableOptionable Beta1.42 Social Links Key ExecutivesKevin T. ConroyChairman, President & Chief Executive OfficerJeffrey Thomas ElliottExecutive VP, Chief Operating & Financial OfficerSandra StatzSenior VP-Clinical & Regulatory AffairsPaul J. LimburgCo-Chief Medical Officer & ScreeningFrederick BaehnerCo-Chief Medical Officer & Precision OncologyKey CompetitorsQuest DiagnosticsNYSE:DGXNateraNASDAQ:NTRALaboratory Co. of AmericaNYSE:LHSarepta TherapeuticsNASDAQ:SRPTCatalentNYSE:CTLTView All CompetitorsInsiders & InstitutionsETF Managers Group LLCBought 6,500 shares on 3/23/2023Ownership: 0.004%Rockefeller Capital Management L.P.Sold 1,409 shares on 3/6/2023Ownership: 0.002%Jacob A OrvilleSold 5,000 sharesTotal: $325,000.00 ($65.00/share)Kevin T ConroySold 10,416 sharesTotal: $636,625.92 ($61.12/share)D Scott CowardSold 4,153 sharesTotal: $253,831.36 ($61.12/share)View All Insider TransactionsView All Institutional Transactions EXAS Stock - Frequently Asked Questions Should I buy or sell Exact Sciences stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXAS shares. View EXAS analyst ratings or view top-rated stocks. What is Exact Sciences' stock price forecast for 2023? 13 analysts have issued 12-month price objectives for Exact Sciences' stock. Their EXAS share price forecasts range from $55.00 to $92.00. On average, they anticipate the company's share price to reach $74.14 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price. View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts. How have EXAS shares performed in 2023? Exact Sciences' stock was trading at $49.51 at the start of the year. Since then, EXAS stock has increased by 33.8% and is now trading at $66.26. View the best growth stocks for 2023 here. Are investors shorting Exact Sciences? Exact Sciences saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 12,380,000 shares, a decline of 5.3% from the February 28th total of 13,070,000 shares. Based on an average daily volume of 2,510,000 shares, the short-interest ratio is currently 4.9 days. View Exact Sciences' Short Interest. When is Exact Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023. View our EXAS earnings forecast. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) posted its earnings results on Tuesday, February, 21st. The medical research company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.18. The medical research company earned $553 million during the quarter, compared to the consensus estimate of $525.61 million. Exact Sciences had a negative net margin of 29.92% and a negative trailing twelve-month return on equity of 19.76%. The company's revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.28) EPS. What ETFs hold Exact Sciences' stock? ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Indxx Medical Devices ETF (MDEV), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH) and First Trust Health Care AlphaDEX Fund (FXH). What guidance has Exact Sciences issued on next quarter's earnings? Exact Sciences updated its FY 2023 earnings guidance on Tuesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.27 billion-$2.31 billion, compared to the consensus revenue estimate of $2.29 billion. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV). What is Exact Sciences' stock symbol? Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS." Who are Exact Sciences' major shareholders? Exact Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (9.03%), Sumitomo Mitsui Trust Holdings Inc. (3.02%), Price T Rowe Associates Inc. MD (2.81%), Baillie Gifford & Co. (2.77%), Nikko Asset Management Americas Inc. (2.74%) and T. Rowe Price Investment Management Inc. (1.65%). Insiders that own company stock include Canada Pension Plan Investment, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Mark Stenhouse, Sarah Condella and Torsten Hoof. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exact Sciences' stock price today? One share of EXAS stock can currently be purchased for approximately $66.26. How much money does Exact Sciences make? Exact Sciences (NASDAQ:EXAS) has a market capitalization of $11.81 billion and generates $2.08 billion in revenue each year. The medical research company earns $-623,510,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. How many employees does Exact Sciences have? The company employs 6,400 workers across the globe. Does Exact Sciences have any subsidiaries? The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..Read More How can I contact Exact Sciences? Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701. This page (NASDAQ:EXAS) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.